



Company Profile:

Raziel Therapeutics is a clinical-stage pharmaceutical company developing RZL-012, an injectable New Chemical Entity (NCE), for Aesthetic indications and fat related disorders. RZL-012 is injected into subcutaneous fat in a single multi-injection session. The product is capable of killing fat cells, resulting in fat volume reduction and improved dimensions in treated areas.

Raziel completed a double blind placebo-controlled phase 2b trial (N=151) in American subjects seeking submental fat (SMF) reduction. Study ended in May 2022 and company met both primary and secondary endpoints. Two SMF phase 3 studies are expected to initiate in Q4 2023.

Another double-blind placebo-controlled phase 2a study has been completed. The study has presented very positive results of the effect of RZL-012 on fat reduction in the flank region.

Raziel signed a license agreement with Fosun Pharma for RZL-012 commercialization in the big China area.

In March 2019 the company received Orphan drug designation from the FDA for treatment of Dercum's disease, a rare fat related disorder. Phase 2B is expected to initiate in H1 2023.

Financing Status

Raziel Therapeutics raised \$30M since establishment.